Base de dados : MEDLINE
Pesquisa : E02.095.147.500.500.500.500 [Categoria DeCS]
Referências encontradas : 3251 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 326 ir para página                         

  1 / 3251 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29157615
[Au] Autor:Jaccard A
[Ad] Endereço:Department of Clinical Hematology, Reference Center for AL Amyloidosis, CHU, 2 Avenue ML King, Limoges 87000, France. Electronic address: arnaud.jaccard@chu-limoges.fr.
[Ti] Título:POEMS Syndrome: Therapeutic Options.
[So] Source:Hematol Oncol Clin North Am;32(1):141-151, 2018 02.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Treatment of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome should be directed at the underlying plasma cell clone with risk-adapted therapy based on the extent of the plasma cell disorder. Radiation therapy is effective for patients with a localized presentation, without bone marrow involvement, and 1 to 3 bone lesions. Patients with disseminated disease should receive, preferably, high-dose chemotherapy with peripheral blood transplantation. Low-dose melphalan and dexamethasone or new agents used in myeloma are also effective. The most promising agent is lenalidomide, which could be given before high-dose therapy or radiation to get rapid neurologic responses.
[Mh] Termos MeSH primário: Síndrome POEMS/terapia
Transplante de Células-Tronco de Sangue Periférico
Talidomida/análogos & derivados
[Mh] Termos MeSH secundário: Aloenxertos
Seres Humanos
Síndrome POEMS/diagnóstico
Síndrome POEMS/patologia
Radioterapia
Talidomida/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
4Z8R6ORS6L (Thalidomide); F0P408N6V4 (lenalidomide)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171122
[St] Status:MEDLINE


  2 / 3251 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384978
[Au] Autor:Nishiwaki S; Sugiura I; Miyata Y; Saito S; Sawa M; Nishida T; Miyamura K; Kuwatsuka Y; Kohno A; Yuge M; Kasai M; Iida H; Kurahashi S; Osaki M; Goto T; Terakura S; Murata M; Nishikawa H; Kiyoi H
[Ad] Endereço:Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya.
[Ti] Título:Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study).
[So] Source:Medicine (Baltimore);96(52):e9568, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) has been dramatically improved since the introduction of tyrosine kinase inhibitors (TKIs). Although allogeneic hematopoietic cell transplantation (allo-HCT) is a major treatment option, the role of autologous peripheral blood stem cell transplantation (auto-PBSCT) has been reconsidered, especially in patients who achieved early molecular remission. METHODS AND ANALYSIS: This is a multicenter exploratory study for Ph + ALL patients aged between 55 and 70 years who achieved complete molecular remission within 3 cycles of chemotherapy. The target sample size is 5, and the registration period is 2 years. The primary endpoint is Day100- mortality after transplantation, and the secondary endpoints are survival, relapse rate, nonrelapse mortality, and adverse events.This study is divided into 3 phases: peripheral blood stem cell harvest, transplantation, and maintenance. Chemomobilization is performed using a combination of cyclophosphamide (CPM), doxorubicin, vincristine (VCR), and prednisolone (PSL). As a preparative regimen, the LEED regimen is used, which consists of melphalan, CPM, etoposide, and dexamethasone. Twelve cycles of maintenance therapy using a combination of VCR, PSL, and dasatinib are performed.In association with relapse, the minimal residual disease (MRD) of BCR-ABL chimeric gene and T-cell subsets are analyzed both before and after auto-PBSCT. ETHICS AND DISSEMINATION: The protocol was approved by the institutional review board of Nagoya University Hospital and all the participating hospitals. Written informed consent was obtained from all patients before registration, in accordance with the Declaration of Helsinki. Results of the study will be disseminated via publications in peer-reviewed journals. TRIAL REGISTRATION: Trial registration number UMIN000026445.
[Mh] Termos MeSH primário: Transplante de Células-Tronco de Sangue Periférico/mortalidade
Transplante de Células-Tronco de Sangue Periférico/métodos
Cromossomo Filadélfia
Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia
[Mh] Termos MeSH secundário: Idoso
Progressão da Doença
Feminino
Genes abl/fisiologia
Seres Humanos
Imunossupressores/administração & dosagem
Masculino
Meia-Idade
Transplante de Células-Tronco de Sangue Periférico/efeitos adversos
Estudos Prospectivos
Proteínas Proto-Oncogênicas c-bcr/biossíntese
Projetos de Pesquisa
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Immunosuppressive Agents); EC 2.7.11.1 (BCR protein, human); EC 2.7.11.1 (Proto-Oncogene Proteins c-bcr)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009568


  3 / 3251 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775695
[Au] Autor:Ben Abdejlil N; Belloumi D; Mâammar M; El Fatimi R; Torjman L; Lakhal A; Jenhani F; Hmida S; Ben Othman T; Ladeb S
[Ad] Endereço:Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.
[Ti] Título:Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country.
[So] Source:Bone Marrow Transplant;52(2):222-227, 2017 Feb.
[Is] ISSN:1476-5365
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study compared retrospectively the effectiveness, toxicity and hematopoietic recovery after autologous peripheral blood stem cell transplantation (ASCT) of two consecutive peripheral blood stem cell mobilization regimens in newly diagnosed MM patients. Patients in group 1 (n=178) were treated with 4 g/m of cyclophosphamide (CY) plus G-CSF (5 µg/kg/day). Patients in group 2 (n=117) with 750 mg/m of VP16 plus G-CSF (10 µg/kg/day). Optimal mobilization, defined by a target number of 8 × 10 CD34+ cells/kg collected, was achieved in 62.4% and 89.7% of patients in groups 1 and 2, respectively (P<10 ). The median number of aphaeresis sessions was reduced from two in group 1 to one in group 2 (P<10 ). Grade neutropenia, febrile neutropenia and IV antibiotic use were significantly more frequent in group 1 than in group 2 (P<10 ). Red blood cell transfusion requirements were significantly greater in group 1 (P=0.007). The switch to VP16-G-CSF resulted in a significant reduction of the number of hospitalization days (P<10 ). Neutrophil and platelet recovery after ASCT occurred on days 11 and 12, respectively, in the two groups with no significant differences. VP +G-CSF allowed liberation of resources in the clinical and aphaeresis departments and demonstrated a better effectiveness-safety profile than CY+G-CSF .
[Mh] Termos MeSH primário: Ciclofosfamida/administração & dosagem
Fator Estimulador de Colônias de Granulócitos/administração & dosagem
Mobilização de Células-Tronco Hematopoéticas/métodos
Mieloma Múltiplo/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Aloenxertos
Feminino
Seres Humanos
Masculino
Meia-Idade
Transplante de Células-Tronco de Sangue Periférico
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
143011-72-7 (Granulocyte Colony-Stimulating Factor); 8N3DW7272P (Cyclophosphamide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1038/bmt.2016.246


  4 / 3251 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28901730
[Au] Autor:Rastogi N; Katewa S; Thakkar D; Kohli S; Nivargi S; Yadav SP
[Ad] Endereço:Pediatric Hematology Oncology Unit, Department of Pediatrics, Fortis Memorial Research Institute, Gurgaon, Haryana, India.
[Ti] Título:Reduced-toxicity alternate-donor stem cell transplantation with posttransplant cyclophosphamide for primary immunodeficiency disorders.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We describe here the outcomes of reduced-toxicity alternate-donor stem cell transplant (SCT) with posttransplant cyclophosphamide (PTCy) for primary immunodeficiency disorders (PIDs) in eight children (haploidentical-seven and matched unrelated donor-one). The conditioning was with serotherapy (alemtuzumab-3/rabbit-anti-thymoglobulin-5); fludarabine, cyclophosphamide, and total body irradiation-5 (additional thiotepa-3); fludarabine and treosulfan-2; and fludarabine and busulfan-1. All received PTCy 50 mg/kg on days 3 and 4 as graft versus host disease prophylaxis along with tacrolimus and mycophenolate. Mean CD34 dose was 13.8 × 10 /kg. Two children died because of PIDs. Acute graft versus host disease up to grades I and II was seen in three children. All six survivors are fully donor and disease free at median follow-up of 753 days. Alternate donor SCT with PTCy is feasible in PID and has good outcomes.
[Mh] Termos MeSH primário: Ciclofosfamida/administração & dosagem
Síndromes de Imunodeficiência/terapia
Transplante de Células-Tronco de Sangue Periférico
Condicionamento Pré-Transplante
Doadores não Relacionados
[Mh] Termos MeSH secundário: Alemtuzumab/administração & dosagem
Aloenxertos
Soro Antilinfocitário/administração & dosagem
Criança
Pré-Escolar
Intervalo Livre de Doença
Seguimentos
Seres Humanos
Síndromes de Imunodeficiência/mortalidade
Lactente
Masculino
Taxa de Sobrevida
Tiotepa/administração & dosagem
Irradiação Corporal Total
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antilymphocyte Serum); 3A189DH42V (Alemtuzumab); 8N3DW7272P (Cyclophosphamide); 905Z5W3GKH (Thiotepa); D7RD81HE4W (thymoglobulin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170914
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26783


  5 / 3251 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28834808
[Au] Autor:Im JS; Abraham SC; Saliba RM; Rondon G; Ross WA; Rashid A; Shpall EJ; Popat U; Qazilbash MH; Hosing C; Oran B; Shah N; Tewari P; Nieto Y; Kebriaei P; Champlin RE; Alousi AM
[Ad] Endereço:Departments of *Stem Cell Transplantation and Cellular Therapy †Pathology ‡Gastroenterology, The University of Texas M.D. Anderson Cancer Center §Department of Pediatric Oncology, Baylor College of Medicine, Houston, TX ∥Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.
[Ti] Título:Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease.
[So] Source:Am J Surg Pathol;41(11):1483-1490, 2017 Nov.
[Is] ISSN:1532-0979
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Histologic confirmation is considered a standard practice to diagnose gastrointestinal graft versus host disease (GI GVHD) and is often used in making treatment decisions. A histologic grade is often determined in cases that are diagnosed with GI GVHD. Although extensive crypt loss (histologic grade 4) is associated with high nonrelapse mortality (NRM), the prognostic value for the more common grade 1 is poorly understood. As clinical decisions are made on the degree of histologic evidence, it is important to establish its prognostic significance. Therefore, we evaluated 309 patients who underwent endoscopic biopsy for suspected GI GVHD within 6 months posttransplant between 2009 and 2012. The presence of histologic grade 1 was associated with increased NRM (hazard ratio=2.7, P=0.02) when compared with one of negative biopsy in patients with lower but not isolated upper GI GVHD. Multivariate competing-risk regression analysis confirmed the independent impact of histologic grade 1 in patients with early clinical stages of lower GI GVHD (stage 0 to 2) (hazard ratio=2.7, P=0.044). When compared with advanced histologic grades, histologic grade 1 did not lessen the adverse outcome for patients with advanced lower GI GVHD (stage 3 to 4) (cumulative incidence NRM of 84%). In conclusion, the presence of histologic grade 1 is associated with increased NRM in patients presenting with lower GI GVHD (stages 0 to 2) and is sufficient evidence for decision to initiate therapy. At the same time, histologic grade 1 does not lessen the markedly adverse impact of advanced lower GI GVHD (stage 3 to 4) and is not synonymous with "mild" GVHD.
[Mh] Termos MeSH primário: Transplante de Medula Óssea/efeitos adversos
Transplante de Células-Tronco de Sangue do Cordão Umbilical/efeitos adversos
Gastroenteropatias/patologia
Trato Gastrointestinal/patologia
Doença Enxerto-Hospedeiro/patologia
Neoplasias Hematológicas/cirurgia
Transplante de Células-Tronco de Sangue Periférico/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Biópsia
Distribuição de Qui-Quadrado
Criança
Pré-Escolar
Endoscopia Gastrointestinal
Feminino
Gastroenteropatias/etiologia
Gastroenteropatias/mortalidade
Doença Enxerto-Hospedeiro/etiologia
Doença Enxerto-Hospedeiro/mortalidade
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Análise Multivariada
Valor Preditivo dos Testes
Prognóstico
Estudos Retrospectivos
Fatores de Risco
Índice de Gravidade de Doença
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1097/PAS.0000000000000914


  6 / 3251 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28623394
[Au] Autor:Li Q; Luo C; Luo C; Wang J; Li B; Ding L; Chen J
[Ad] Endereço:Shanghai Children's Medical Center, Affiliated Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
[Ti] Título:Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes.
[So] Source:Ann Hematol;96(8):1389-1397, 2017 Aug.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Hematopoietic stem cell transplantation (HSCT) using an optimized conditioning regimen is essential for the long-term survival of patients with inherited bone marrow failure syndromes (IBMFS). We report HSCT in 24 children with Fanconi anemia (FA, n = 12), Diamond-Blackfan anemia (DBA, n = 7), and dyskeratosis congenita (DC, n = 5) from a single HSCT center. The graft source was peripheral blood stem cells (n = 19) or cord blood stem cells (n = 5). FA and DC patients received reduced-intensity conditioning, while DBA patients had myeloablative conditioning. The median numbers of infused mononuclear cells and CD34+ cells were 14.20 × 10 /kg and 4.3 × 10 /kg, respectively. The median time for neutrophil and platelet recovery was 12 and 18 days, respectively. Complete donor engraftment was achieved in 23 of 24 patients. There was one primary graft failure. During a median follow-up of 27.5 months (range, 2-130 months), the overall survival in all patients was 95.8%. The incidence of grade II-III acute graft versus host disease (GvHD) and chronic GvHD was 29.2% and 16.7%, respectively. We conclude that HSCT can be a curative option for patients with IBMFS. Modification of the conditioning regimen based on the type of disease may lead to encouraging long-term outcomes.
[Mh] Termos MeSH primário: Anemia Aplástica/terapia
Doenças da Medula Óssea/terapia
Transplante de Células-Tronco de Sangue do Cordão Umbilical/métodos
Transplante de Células-Tronco Hematopoéticas/métodos
Hemoglobinúria Paroxística/terapia
Transplante de Células-Tronco de Sangue Periférico/métodos
[Mh] Termos MeSH secundário: Adolescente
Anemia de Diamond-Blackfan/terapia
Criança
Pré-Escolar
Transplante de Células-Tronco de Sangue do Cordão Umbilical/efeitos adversos
Seleção do Doador
Disceratose Congênita/terapia
Anemia de Fanconi/terapia
Feminino
Doença Enxerto-Hospedeiro/diagnóstico
Doença Enxerto-Hospedeiro/etiologia
Transplante de Células-Tronco Hematopoéticas/efeitos adversos
Hematúria/diagnóstico
Hematúria/etiologia
Seres Humanos
Lactente
Estimativa de Kaplan-Meier
Masculino
Avaliação de Resultados (Cuidados de Saúde)
Transplante de Células-Tronco de Sangue Periférico/efeitos adversos
Condicionamento Pré-Transplante
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170618
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3041-7


  7 / 3251 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28514773
[Au] Autor:Ruiz-Argüelles GJ; León-Peña AA; León-González M; Nuñez-Cortes AK; Olivares-Gazca JC; Murrieta-Alvarez I; Vargas-Espinosa J; Medina-Ceballos E; Cantero-Fortiz Y; Ruiz-Argüelles A; Ruiz-Delgado MA; Ruiz-Delgado RJ; Ruiz-Reyes G; Priesca-Marín M; Torres-Priego MS; Blumenkron-Marroquin D; Ruiz-Delgado GJ
[Ad] Endereço:Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico.
[Ti] Título:A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells.
[So] Source:Acta Haematol;137(4):214-219, 2017.
[Is] ISSN:1421-9662
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: With the goal of achieving immune system reset, autologous hematopoietic stem cell transplantations have been performed in patients with multiple sclerosis (MS). MATERIAL AND METHODS: Two hundred and eighty-six consecutive patients with MS were autografted in a single center using non-frozen peripheral blood stem cells (PBSCs), on an outpatient basis and conditioning with cyclophosphamide and rituximab. The protocol was registered in ClinicalTrials.gov identifier NCT02674217. RESULTS: One hundred and ninety-four females and 92 males were included; the median age was 47. All procedures were started on an outpatient basis and only 8 persons needed to be admitted to the hospital during the procedure. In order to obtain at least 1 × 106/kg viable CD34 cells, 1-4 aphereses were performed (median 1). The total number of viable CD34+ cells infused ranged between 1 and 19.2 × 106/kg (median 4.6). Patients recovered above 0.5 × 109/L absolute granulocytes on median day 8 (range 0-12). Two individuals needed red blood cells but none needed platelet transfusions. There were no transplant-related deaths and the 128-month overall survival of the patients is 100%. In 82 persons followed up for 3 or more months, the Expanded Disability Status Scale diminished from a mean of 5.2-4.9, the best results being obtained in relapsing-remitting and primary progressive MS. CONCLUSIONS: It is possible to conduct autotransplants for patients with MS employing non-frozen PBSCs and outpatient conduction. Additional information is needed to assess the efficacy of these procedures in the treatment of patients with MS.
[Mh] Termos MeSH primário: Esclerose Múltipla/terapia
Transplante de Células-Tronco de Sangue Periférico/métodos
[Mh] Termos MeSH secundário: Adulto
Assistência Ambulatorial
Remoção de Componentes Sanguíneos
Criopreservação
Estudos de Viabilidade
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Condicionamento Pré-Transplante
Transplante Autólogo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170518
[St] Status:MEDLINE
[do] DOI:10.1159/000469655


  8 / 3251 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28439877
[Au] Autor:Arai Y; Kondo T; Shigematsu A; Tanaka J; Ohashi K; Fukuda T; Kawakita T; Mori T; Hoshino T; Onizuka M; Ozawa Y; Yoshida S; Ueda Y; Mizuno I; Atsuta Y; Mizuta S; Japan Society for Haematopoietic Cell Transplantation
[Ad] Endereço:Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
[Ti] Título:Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults.
[So] Source:Br J Haematol;178(1):106-111, 2017 Jul.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The efficacy of high-dose cytarabine (HDCA) plus cyclophosphamide/total-body irradiation (CY/TBI) has been proved in cord blood transplantation (CBT) for acute lymphoblastic leukaemia (ALL), but not in bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT). In this cohort study, we compared the prognosis of CY/TBI (N = 1244) and HDCA/CY/TBI (N = 316) regimens in BMT/PBSCT for ALL. The addition of HDCA decreased post-transplant relapse, while significantly increasing non-relapse mortality (risk ratio, 1·33), and overall survival was not improved. The positive effects of HDCA reported in CBT cannot be extrapolated to BMT/PBSCT, and HDCA may not be recommended in these procedures.
[Mh] Termos MeSH primário: Transplante de Medula Óssea/métodos
Citarabina/efeitos adversos
Transplante de Células-Tronco de Sangue Periférico/métodos
Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico
Condicionamento Pré-Transplante/métodos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Transplante de Medula Óssea/efeitos adversos
Terapia Combinada
Ciclofosfamida/administração & dosagem
Ciclofosfamida/efeitos adversos
Citarabina/administração & dosagem
Feminino
Seres Humanos
Japão/epidemiologia
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Transplante de Células-Tronco de Sangue Periférico/efeitos adversos
Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia
Prognóstico
Recidiva
Sistema de Registros
Condicionamento Pré-Transplante/efeitos adversos
Irradiação Corporal Total
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
04079A1RDZ (Cytarabine); 8N3DW7272P (Cyclophosphamide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14652


  9 / 3251 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28331129
[Au] Autor:Tanaka H; Ishii A; Sugita Y; Shimizu R; Sato F; Sakuma Y; Iwai R; Kakuta S
[Ad] Endereço:Department of Hematology, Asahi General Hospital.
[Ti] Título:Impact of Hematopoietic Progenitor Cell Count as an Indicator for Optimal Timing of Peripheral Stem Cell Harvest in Clinical Practice.
[So] Source:J Clin Exp Hematop;56(3):150-159, 2017.
[Is] ISSN:1880-9952
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:For optimizing CD34+ cell collection, appropriately timing peripheral blood stem cell harvest (PBSCH) initiation is crucial. Automatic cell analyzers with the immature myeloid information channel provide hematopoietic progenitor cell (HPC) count, a surrogate marker of CD34+ cells, which can be obtained within a few minutes without requiring monoclonal antibodies. The final decision on PBSCH initiation can be made using the HPC count obtained on the morning of the harvest day. Herein, we evaluated the impact of the HPC count as an indicator for the optimal timing of PBSCH in clinical practice over 9 years. One hundred and eighteen aphereses from 72 cases had a definite number of CD34+ cells/kg in the PBSC yield. A correlation was found between the HPC count in the PB and the CD34+ cell count (R = 0.563, p < 0.001), whereas no correlation existed between the white blood cell and CD34+ cell counts (R = 0.0418, p = 0.65). We defined > 2.0 × 10 /kg of CD34+ cells in a single apheresis as good mobilization. Multivariate analysis demonstrated that an HPC count of > 21/µL, myeloblast count of > 12/µL, and age at PBSCH of < 50 years were independently associated with good mobilization (p = 0.001, p < 0.001, and p = 0.005, respectively). Our findings suggest that the HPC count is a good indicator for the optimal timing of PBSCH.
[Mh] Termos MeSH primário: Antígenos CD34/análise
Mobilização de Células-Tronco Hematopoéticas/métodos
Células-Tronco Hematopoéticas/citologia
Células-Tronco de Sangue Periférico/citologia
[Mh] Termos MeSH secundário: Adulto
Feminino
Mobilização de Células-Tronco Hematopoéticas/normas
Seres Humanos
Leucaférese/métodos
Leucaférese/normas
Contagem de Leucócitos
Masculino
Meia-Idade
Transplante de Células-Tronco de Sangue Periférico/métodos
Padrões de Prática Médica/normas
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD34)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170410
[Lr] Data última revisão:
170410
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE
[do] DOI:10.3960/jslrt.56.150


  10 / 3251 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28320172
[Au] Autor:Hayashi Y; Kimura A; Nakamura H; Mimuro M; Iwasaki Y; Hara A; Yoshida M; Inuzuka T
[Ad] Endereço:Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan. Electronic address: hayashiy@gifu-u.ac.jp.
[Ti] Título:Neuropathological findings from an autopsied case showing posterior reversible encephalopathy syndrome-like neuroradiological findings associated with premedication including tacrolimus for autologous peripheral blood stem cell transplantation.
[So] Source:J Neurol Sci;375:382-387, 2017 Apr 15.
[Is] ISSN:1878-5883
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Posterior reversible encephalopathy syndrome (PRES) is diagnosed based on neuroradiological findings. Typically, PRES is reversible and presents with a good outcome; however, fatal outcomes have been reported. We report an autopsied case showing PRES-like neuroradiological findings associated with premedication including tacrolimus for autologous peripheral blood stem cell transplantation in a 28-year-old woman with a 2-year history of acute myeloid sarcoma/acute myeloid leukemia. Neurological examination revealed disturbed consciousness, muscle weakness in all extremities, and bilaterally diminished tendon reflexes. Brain fluid attenuated inversion recovery MRI showed multiple bilateral hyper-intensity areas in the posterior white matter and left corona radiate. She died of respiratory arrest within 24h after PRES diagnosis. Neuropathological examination revealed diffuse cerebral edema, multiple cerebral hematomas that extended into the lateral ventricles and subarachnoid cavities, and multiple microbleeds predominantly in the inferior surface of the occipital white matter. Microscopic findings revealed paler myelin sheaths, enlargement of the vascular endothelium, leakage of plasma components and red blood cells, and clasmatodendrosis within the occipital white matter. Cerebral herniation and diffuse cerebral edema due to vascular endothelial dysfunction were concluded to be the cause of death. These pathological findings may aid in the pathophysiological recognition of acute-stage PRES.
[Mh] Termos MeSH primário: Imunossupressores/uso terapêutico
Transplante de Células-Tronco de Sangue Periférico/métodos
Síndrome da Leucoencefalopatia Posterior
Tacrolimo/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Autopsia
Feminino
Fluordesoxiglucose F18/metabolismo
Seres Humanos
Processamento de Imagem Assistida por Computador
Imagem por Ressonância Magnética
Tomografia por Emissão de Pósitrons
Síndrome da Leucoencefalopatia Posterior/diagnóstico por imagem
Síndrome da Leucoencefalopatia Posterior/tratamento farmacológico
Síndrome da Leucoencefalopatia Posterior/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 0Z5B2CJX4D (Fluorodeoxyglucose F18); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170705
[Lr] Data última revisão:
170705
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170322
[St] Status:MEDLINE



página 1 de 326 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde